Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

NCT00422799 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Waldenstrom's Macroglobulinemia

Interventions

DRUG: Bortezomib
DRUG: Rituximab

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]